AI Reasoning Model Helps Identify Leads for Rare Disease Diagnoses
A study reports that an OpenAI reasoning model improved rare disease diagnostic yield by 4.8% in previously unsolved cases, offering new leads after specialist analysis.
A study reports that an OpenAI reasoning model improved rare disease diagnostic yield by 4.8% in previously unsolved cases, offering new leads after specialist analysis.
The PTC Harmony 96 and PTC Harmony Deepwell systems are designed to provide high-performance PCR for academic and biopharma laboratories.
Results from the NHS-Galleri study show a 26% reduction in metastatic cancer diagnoses by the third round of screening.
The multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read MoreThe Callisto Sample Prep System application is optimized for the PromethION platform to support whole genome sequencing workflows.
Read MoreThe settlement follows a criminal conviction and addresses more than $174 million in fraudulent Medicare claims involving multiple laboratories.
Read MoreThe funding will support commercial expansion of the company’s blood-based diagnostic tests and the appointment of a new president and chief operating officer.
Read MoreResearch presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read MoreEmerging Andes virus cases—capable of person-to-person transmission—are prompting US clinical labs to reassess hantavirus protocols and consider travel and epidemiologic exposures beyond rodent contact.
Read MoreCo-Diagnostics has completed its assay development strategy for Bundibugyo virus, following the WHO’s emergency declaration and CDC’s updated traveler screening measures amid ongoing Ebola outbreaks in the DRC and Uganda.
Read MoreThe tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read MoreThe FDA has approved Guardant360 Liquid CDx, a blood-based test that integrates genomic and epigenomic profiling for advanced cancer, offering a broader genomic footprint and faster results.
Read MoreTGen has launched JAYseq, a clinical whole genome sequencing test for multiple myeloma that delivers results in 72 hours, enabling rapid identification of genetic changes and immunotherapy targets, according to the institute.
Read MoreResearchers at Vanderbilt-Ingram Cancer Center report that RNA sequencing of blood samples can predict immunotherapy response in high-risk breast cancer patients.
Read MoreDiasorin has received FDA 510(k) clearance for its customizable LIAISON PLEX Gastrointestinal Flex Assay, allowing labs to select from 24 targets to tailor testing based on patient needs and operational priorities.
Read MoreA multicenter clinical trial found the HelioLiver blood test detected early-stage liver cancer with 71.9% sensitivity, outperforming ultrasound’s 36.8%.
Read MoreYourgene Health has launched the Yourgene Insight DPYD assay, expanding detection to 19 variants for DPD deficiency screening in cancer patients receiving 5-fluorouracil, with same-day results and initial Research Use Only availability.
Read MoreResearchers at Mass General Brigham have developed a digital seed amplification assay that detects TDP-43 protein seeds in cerebrospinal fluid, enabling identification of FTLD-TDP, a specific frontotemporal lobar degeneration subtype.
Read More